Anvisa requires prescriptions for weight-loss pens in Brazil

The Brazilian health agency Anvisa now requires prescriptions for GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, to curb misuse. This change aims to combat the unauthorized and off-label use of these weight-loss medications. The decision, effective Wednesday, mandates valid prescriptions for purchasing these "weight-loss pens." Recent studies reveal both positive and negative effects of these drugs, which mimic an intestinal hormone, including potential benefits for alcohol consumption and Alzheimer's, but also risks like vision problems and hair loss. Anvisa's move follows concerns about adverse effects, with 32% of reported issues linked to off-label use. The agency warns against using these medications outside of scientifically proven indications, emphasizing potential health risks.